T-cell activation by recombinant receptors: CD28 costimulation is required for interleukin 2 secretion and receptor-mediated T-cell proliferation but does not affect receptor-mediated target cell lysis.
暂无分享,去创建一个
B. Seliger | H. Abken | C. Pohl | A. Hombach | C. Heuser | C. Schneider | D. Sent | D. Koch | Barbara Seliger | Dagmar Sent | Claudia Schneider | Barbara Seliger | Dimitra Koch
[1] V. Diehl,et al. An entirely humanized CD3 ζ‐chain signaling receptor that directs peripheral blood t cells to specific lysis of carcinoembryonic antigen–positive tumor cells , 2000, International journal of cancer.
[2] V. Diehl,et al. T cell activation by recombinant FcεRI γ-chain immune receptors: an extracellular spacer domain impairs antigen-dependent T cell activation but not antigen recognition , 2000, Gene Therapy.
[3] J. Frelinger,et al. Naive CD8+ T Cells Do Not Require Costimulation for Proliferation and Differentiation into Cytotoxic Effector Cells1 , 2000, The Journal of Immunology.
[4] M. Krummel,et al. Differential coupling of second signals for cytotoxicity and proliferation in CD8+ T cell effectors: amplification of the lytic potential by B7. , 1999, Journal of immunology.
[5] Seliger,et al. Gene Transfer of the Co‐Stimulatory Molecules B7‐1 and B7‐2 Enhances the Immunogenicity of Human Renal Cell Carcinoma to a Different Extent , 1999, Scandinavian journal of immunology.
[6] M. Mescher,et al. ICAM‐1 and B7‐1 provide similar but distinct costimulation for CD8+ T cells, while CD4+ T cells are poorly costimulated by ICAM‐1 , 1999, European journal of immunology.
[7] M. Weijtens,et al. A retroviral vector system ‘STITCH’ in combination with an optimized single chain antibody chimeric receptor gene structure allows efficient gene transduction and expression in human T lymphocytes , 1998, Gene Therapy.
[8] B. V. van Krimpen,et al. Chimeric scFv/γ receptor‐mediated T‐cell lysis of tumor cells is coregulated by adhesion and accessory molecules , 1998, International journal of cancer.
[9] J. Langhorne,et al. A flow cytometric method to assess antigen-specific proliferative responses of different subpopulations of fresh and cryopreserved human peripheral blood mononuclear cells. , 1998, Journal of immunological methods.
[10] V. Diehl,et al. A chimeric receptor that selectively targets membrane-bound carcinoembryonic antigen (mCEA) in the presence of soluble CEA , 1998, Gene Therapy.
[11] V. Diehl,et al. An anti-CD30 chimeric receptor that mediates CD3-zeta-independent T-cell activation against Hodgkin's lymphoma cells in the presence of soluble CD30. , 1998, Cancer research.
[12] T. Mak,et al. Duration of TCR stimulation determines costimulatory requirement of T cells. , 1996, Immunity.
[13] J. Sprent,et al. Influence of antigen dose and costimulation on the primary response of CD8+ T cells in vitro , 1996, The Journal of experimental medicine.
[14] S. Rosenberg,et al. In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes. , 1995, Cancer research.
[15] M. Croft,et al. Costimulatory requirements of naive CD4+ T cells. ICAM-1 or B7-1 can costimulate naive CD4 T cell activation but both are required for optimum response. , 1995, Journal of immunology.
[16] U. Şahin,et al. The role of lymphocyte subsets and adhesion molecules in T cell‐dependent cytotoxicity mediated by CD3 and CD28 bispecific monoclonal antibodies , 1995, European journal of immunology.
[17] J. Bluestone,et al. The B7 and CD28 receptor families. , 1994, Immunology today.
[18] B. Groner,et al. Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2-expressing tumor cells. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[19] V. Diehl,et al. CD30‐specific AB1‐AB2‐AB3 internal image antibody network: Potential use as anti‐idiotype vaccine against Hodgkin's lymphoma , 1993, International journal of cancer.
[20] Z. Eshhar,et al. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[21] J. Kirkwood,et al. Improved short- and long-term XTT-based colorimetric cellular cytotoxicity assay for melanoma and other tumor cells. , 1992, Journal of immunological methods.
[22] V. Diehl,et al. Antitumor effects of ricin A chain immunotoxins prepared from intact antibodies and Fab' fragments on solid human Hodgkin's disease tumors in mice. , 1990, Cancer research.
[23] U. Reinhold,et al. Can combined T-cell- and antibody-based immunotherapy outsmart tumor cells? , 1998, Immunology today.
[24] P. Morel,et al. Crossregulation between Th1 and Th2 cells. , 1998, Critical reviews in immunology.
[25] V. Kuchroo,et al. CD28/B7 costimulation: a review. , 1998, Critical reviews in immunology.
[26] W. Dippold,et al. Humanized anti-carcinoembryonic antigen antibody: strategies to enhance human tumor cell killing. , 1993, The Year in immunology.